Relay Therapeutics Delivers Strategic Update at Jefferies London Healthcare Conference 2025

At the recent Jefferies LLC London Healthcare Conference, Relay Therapeutics, Inc. (Nasdaq: RLAY) laid out its 2025 strategic path and clinical‑development milestones underlined by its lead asset RLY‑2608. CEO Sanjiv Patel emphasized the company is firmly in “execution mode”, pointing to the ongoing Phase III trial of RLY‑2608, a PI3Kα‑mutant selective inhibitor positioned as the first of its kind in the clinic. Patel described plans to explore earlier‑line settings in HR+/HER2– breast cancer via triplet regimens, and highlighted that dosing has also begun for patients with PI3Kα‑driven vascular malformations. The company reported approximately US$600 million in cash on hand, reinforcing its ability to execute across multiple programs. During Q&A, Jefferies’ Zaki Molvi referenced prior interim data — a 39% objective response rate (ORR) and a median progression‑free survival (PFS) of 10.3 months overall, and 11.0 months in a pure second‑line cohort. In summary: Relay is pivoting from discovery into advanced clinical execution, deploying RLY‑2608 in both oncology (mutant PI3Kα breast cancer) and rare disease (vascular malformations) settings, backed by a strong balance sheet and a plan to expand into earlier treatment lines. #RelayTherapeutics #RLY2608 #PrecisionOncology #BiotechUpdate #SlimScan #GrowthStocks #CANSLIM